Modulation of heme oxygenase-1 by metalloporphyrins increases anti-viral T cell responses

Clin Exp Immunol. 2015 Feb;179(2):265-76. doi: 10.1111/cei.12451.

Abstract

Heme oxygenase (HO)-1, the inducible isoform of HO, has immunomodulatory functions and is considered a target for therapeutic interventions. In the present study, we investigated whether modulation of HO-1 might have regulatory effects on in-vitro T cell activation. The study examined whether: (i) HO-1 induction by cobalt-protoporphyrin (CoPP) or inhibition by tin-mesoporphyrin (SnMP) can affect expansion and function of virus-specific T cells, (ii) HO-1 modulation might have a functional effect on other cell populations mediating effects on proliferating T cells [e.g. dendritic cells (DCs), regulatory T cells (T(regs)) and natural killer cells] and (iii) HO-1-modulated anti-viral T cells might be suitable for adoptive immunotherapy. Inhibition of HO-1 via SnMP in cytomegalovirus (CMV)pp65-peptide-pulsed peripheral blood mononuclear cells (PBMCs) led to increased anti-viral T cell activation and the generation of a higher proportion of effector memory T cells (CD45RA(-) CD62L(-)) with increased capability to secrete interferon (IFN)-γ and granzyme B. T(reg) depletion and SnMP exposure increased the number of anti-viral T cells 15-fold. To test the possibility that HO-1 modulation might be clinically applicable in conformity with good manufacturing practice (GMP), SnMP was tested in isolated anti-viral T cells using the cytokine secretion assay. Compared to control, SnMP treatment resulted in higher cell counts and purity without negative impact on quality and effector function [CD107a, IFN-γ and tumour necrosis factor (TNF)-α levels were stable]. These results suggest an important role of HO-1 in the modulation of adaptive immune responses. HO-1 inhibition resulted in markedly more effective generation of functionally active T cells suitable for adoptive T cell therapy.

Keywords: HO-1 modulation; antigen-specific T cells; immunotherapy; metalloporphyrins.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adoptive Transfer
  • Cytomegalovirus / immunology*
  • Cytomegalovirus Infections / immunology*
  • Cytomegalovirus Infections / pathology
  • Cytomegalovirus Infections / therapy
  • Dendritic Cells / immunology
  • Female
  • Heme Oxygenase-1 / immunology*
  • Humans
  • Immunity, Cellular*
  • Immunologic Memory
  • Interferon-gamma / immunology
  • Male
  • Metalloporphyrins / pharmacology*
  • Phosphoproteins / immunology
  • T-Lymphocytes, Regulatory / immunology*
  • T-Lymphocytes, Regulatory / pathology
  • T-Lymphocytes, Regulatory / transplantation
  • Tumor Necrosis Factor-alpha / immunology
  • Viral Matrix Proteins / immunology

Substances

  • IFNG protein, human
  • Metalloporphyrins
  • Phosphoproteins
  • Tumor Necrosis Factor-alpha
  • Viral Matrix Proteins
  • cytomegalovirus matrix protein 65kDa
  • Interferon-gamma
  • HMOX1 protein, human
  • Heme Oxygenase-1